Project measures / variables set:   Wiltshire4   monocytes_Ida

ID, description, units MPD:52453   monocytes_Ida   monocytes, percent viability   [%]  
idarubicin study
Measures • dose [µM]:    • control    • 0.046    • 0.137    • 1.235    • 11.1    • 100
Data set, strains Wiltshire4   inbred w/CC7   35 strains     sex: m     age: 10wks
Procedure immune cell quantification
Comparisoncontrol group vs. multiple treatment / dosage groups
Ontology mappings

  SIDE-BY-SIDE STRAIN CURVES
Values
Graph Type
Dimensions Width:  ×  Height: px
Plot Options


  OVERLAPPING STRAIN CURVES
Data
Dimensions px
Toggle Series   
Plot Options

Wiltshire4 - monocytes, percent viability





  ANOVA, Q-Q NORMALITY ASSESSMENT

ANOVA Summary     

Factor DF Sum of squares Mean sum of squares F value p-value (Pr>F)
dose 5 850873.0713 170174.6143 1243.9574 < 0.0001
dose:strain 170 81745.2836 480.8546 3.515 < 0.0001
Residuals 608 83175.0051 136.801
strain 34 59407.9408 1747.2924 12.7725 < 0.0001

Q-Q normality assessment based on residuals

  


  INDIVIDUAL MEASURES
ProjectIDTreatmentMeasure / Variable Description PanelStrains
tested
SexAge
Wiltshire4 52453 immune cell quantification idarubicin monocytes, percent viability   [%]   control  monocytes_Ida_ctrl inbred w/CC7 35 m 10wks
Wiltshire4 52454 immune cell quantification idarubicin monocytes, percent viability   [%]   dose: 0.046 µM  monocytes_Ida_A inbred w/CC7 35 m 10wks
Wiltshire4 52455 immune cell quantification idarubicin monocytes, percent viability   [%]   dose: 0.137 µM  monocytes_Ida_B inbred w/CC7 35 m 10wks
Wiltshire4 52456 immune cell quantification idarubicin monocytes, percent viability   [%]   dose: 1.235 µM  monocytes_Ida_C inbred w/CC7 35 m 10wks
Wiltshire4 52457 immune cell quantification idarubicin monocytes, percent viability   [%]   dose: 11.1 µM  monocytes_Ida_D inbred w/CC7 35 m 10wks
Wiltshire4 52458 immune cell quantification idarubicin monocytes, percent viability   [%]   dose: 100 µM  monocytes_Ida_E inbred w/CC7 35 m 10wks